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Anti-thymocyte globulin (ATG) is a lymphocyte depleting agent applied in hematopoietic
stem cell transplantation (HSCT) to prevent rejection and Graft-vs.-Host Disease (GvHD).
In this study, we compared two rabbit ATG products, ATG-Genzyme (ATG-GENZ), and
ATG-Fresenius (ATG-FRES), with respect to dosing, clearance of the active lymphocyte
binding component, post-HSCT immune reconstitution and clinical outcome. Fifty-eigth
pediatric acute leukemia patients (n = 42 ATG-GENZ, n = 16 ATG-FRES), who received
a non-depleted bone marrow or peripheral blood stem cell graft from an unrelated donor
were included. ATG-GENZ was given at a dosage of 6–10 mg/kg; ATG-FRES at 45–60
mg/kg. The active component of ATG from both products was cleared at different rates.
Within the ATG-FRES dose range no differences were found in clearance of active ATG
or T-cell re-appearance. However, the high dosage of ATG-GENZ (10 mg/kg), in contrast
to the low dosage (6–8 mg/kg), correlated with prolonged persistence of active ATG and
delayed T-cell reconstitution. Occurrence of serious acute GvHD (grade III–IV) was highest
in the ATG-GENZ-low dosage group. These results imply that dosing of ATG-GENZ is
more critical than dosing of ATG-FRES due to the difference in clearance of active ATG.
This should be taken into account when designing clinical protocols.
Keywords: ATG, Genzyme, Fresenius, serotherapy, pediatrics, acute GvHD
INTRODUCTION
Serotherapy with lymphocyte depleting antibodies, particularly anti-thymocyte globulin (ATG) and
alemtuzumab, is frequently applied as part of the conditioning regimen in allogeneic hematopoietic
stem cell transplantation (HSCT). Its major aim is to reduce the risk of Graft-vs.-Host Disease
(GvHD) and graft rejection. ATG targets cells of the immune system, such as T-cells (1–3),
through various mechanisms (3, 4). ATG products are polyclonal IgG antibodies, raised in
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horses or rabbits by immunization with human thymocytes
(horse: ATGAM R©, Pfizer, New York, NY, USA; rabbit ATG-
Genzyme, ATG-GENZ, Thymoglobulin R©, Sanofi Genzyme,
Cambridge, MA, USA), or with a Jurkat T-cell line (rabbit
ATG-Fresenius, ATG-FRES, recently re-named as anti-human
T-lymphocyte immunoglobulin ATLG, Grafalon R©, Neovii
Biotech, Rapperswil, Switzerland). Both ATG-GENZ and
ATG-FRES not only target T-cells but also, amongst others,
neutrophils, monocytes, NK-, B-cells and non-immune cells
like endothelial cells (5). However, due to the differences in
manufacturing procedures, both products contain different
specificities and quantity of antibodies (5, 6). As a consequence,
the lymphodepleting potency of the two rabbit ATG products,
ATG-GENZ and ATG-FRES, differs, which is reflected in the
historically recommended total dosage for use in pre-HSCT
conditioning, i.e., in children 10 mg/kg for ATG-GENZ and 60
mg/kg for ATG-FRES (7–10). The preferential use of either ATG
product depends on (inter)national guidelines, disease protocol
or the physicians choice (5, 11, 12). Active ATG is defined as
the fraction of ATG that is capable of binding to lymphocytes.
Its presence in serum or plasma can be determined by flow
cytometry (13). Active ATG makes up only < 10% of the total
rabbit IgG (total ATG). The clearance of active ATG has, in
contrast to clearance of total rabbit IgG, a major impact on
immune recovery and clinical outcome post-HSCT (7–9, 11, 14–
16). The level of active ATG of 1 AU/mL is considered the
threshold above which T-cell reconstitution is never observed
(15). Therefore, the optimal approach for monitoring ATG is
regular measurement of active ATG levels, rather than total
ATG (rabbit IgG).
In several recent reports, ATG-GENZ and ATG-FRES were
compared as part of the conditioning regimen pre-HSCT (10,
17–21) or as induction treatment in solid organ transplant
recipients (22). With one exception (10), these studies suggest
that immune recovery is delayed after usage of ATG-GENZ
compared to ATG-FRES with controversial data regarding the
impact on clinical outcome (18–22). However, reports comparing
active ATG-GENZ and ATG-FRES are lacking. In addition, in
various international protocols the dosages of ATG-GENZ as
well as ATG-FRES have recently been reduced, with the aim
to promote more rapid immune recovery, Graft-vs.-Leukemia
(GvL) and protection against infections (23–27). Therefore,
the aim of the present study was to compare the clearance
of the active components after dose reduction of ATG-GENZ
and ATG-FRES post-HSCT and to investigate the impact on
immune recovery, viral infections and the incidence of acute and
chronic GvHD in a homogeneous cohort of children receiving
allogeneic HSCT.
PATIENTS AND METHODS
Patients
Children treated between 2010 and 2016 for acute lymphoblastic
(ALL) or acute myeloid leukemia (AML) with an allogeneic
HSCT and receiving ATG as part of the pre-HSCT myeloablative
conditioning regimen were eligible for this study. Patients were
transplanted in the Leiden University Medical Center (n= 38) or
the Copenhagen University Hospital Rigshospitalet (n= 20) with
a non-depleted bone marrow (BM) or peripheral blood stem cell
(PBSC) graft from an unrelated donor. All patients and donors
were genotyped using high resolution typing for HLA class I
and II alleles (10 antigens: -A, -B, -C, -DR∗B1, -DQ∗B1). HLA-
matched donors were defined as 10 out of 10 matched. Standard
care consisted of protective isolation and infection prophylaxis,
both performed in accordance with institutional guidelines. No
cytomegalovirus (CMV), Epstein-Barr virus (EBV) or human
adenovirus (HAdV) prophylaxis was used. Surveillance of viral
reactivation was performed during the period after HSCT, up to
time of T-cell recovery, through measuring plasma DNA load
twice a week. GvHD prophylaxis consisted of cyclosporine A
(CsA) and methotrexate (MTX) (n = 52), tacrolimus in case of
CsA intolerance (n = 1) or a combination of CsA/MTX and
mycophenolate mofetil (MMF) (n = 5). In the study cohort of
58 patients (Table 1), ATG-GENZ was given at the historical
dosage of 10 mg/kg (n= 24) or the lowered dosage of 6–8 mg/kg
(n= 18) and ATG-FRES at 60 mg/kg (n= 9) or 45 mg/kg (n= 7)
(Supplementary Table 1). Immune cell recovery up to 1 year,
incidence of viral infections up to 180 days, occurrence of acute
GvHDup to 100 days post-HSCT, chronic GvHDup to 1 year and
cumulative incidence of relapse and overall survival up to 5 years
were investigated as outcome parameters. Patients were excluded
for further analysis of immune recovery when late graft rejection
and early leukemia relapse occurred. Immune reconstitution of
patients who received ATG was compared with data obtained
from 22 children transplanted for acute leukemia with an
HLA identical donor, without serotherapy in the conditioning
(Leiden n = 13, Copenhagen n = 9). Institutional review boards
approved this study (Leiden, P01.028; Copenhagen, ATG H-1-
2010-009/H-7-2014-016), and informed consent was obtained
from all patients and/or their legal guardians in accordance with
the declaration of Helsinki.
Rabbit IgG and Active ATG
ATG levels were measured in sera/plasma samples taken
before start of the conditioning therapy, at the day of graft
infusion and at 1, 2, 3, 4, 8, and 13 weeks thereafter. An
additional sample was collected from Leiden patients at 6
weeks post-HSCT. Samples were collected as clotted or EDTA-
anti-coagulated blood, centrifuged shortly after collection and
stored at−20 or−80◦C.
Concentrations of rabbit IgG (total ATG) were measured by
ELISA (28). Microtiter plates were coated with goat anti-rabbit
IgG adsorbed for human IgG (Jackson Europe, Suffolk, UK).
After blocking and washing, a standard curve of ATG-GENZ
(Thymoglobulin, range 4–250 ng/mL) and diluted patients sera
(start at least 1:100, 2-fold dilutions) were incubated for 1 h,
followed by washing and incubation with alkaline phosphatase-
conjugated goat anti-rabbit IgG adsorbed for human IgG
(Jackson Europe).
In a modification of the method described earlier, active ATG,
the fraction of the product capable of binding to cells, was
measured in serum or plasma samples using a quantitative flow
cytometry assay (29). In short, HUT-78 T-cells were incubated
with 4-fold dilutions of patient’s serum/plasma, starting with a
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TABLE 1 | Patient characteristics ATG-Genzyme and ATG-Fresenius groups.
ATG Genzyme ATG Fresenius p-value
Number of patients 42 16
TRANSPLANT CENTER, n (%)
Leiden 38 (90)
Copenhagen 4 (10) 16 (100)
Patient age, years;
median (range)
9 (1–18) 6 (1–17) 0.248
DIAGNOSIS, n (%)
Acute lymphoblastic
leukemia
17 (40) 16 (100) <0.001
Acute myeloid leukemia 25 (60) –
DONOR, n (%)
HLA match 10/10 30 (71) 13 (81) 0.52
HLA match 8–9/10 12 (29) 3 (19)
STEM CELL SOURCE, n (%)
Bone marrow 34 (81) 14 (87) 0.71
Peripheral blood 8 (19) 2 (13)
TOTAL NC DOSE, 108/kg BW; median (range)
Bone marrow graft 2.8 (0.6–9.6) 5.5 (2.3–7.9) 0.02
Peripheral blood graft 8.3 (5.0–16.4) 16.1* –
SEROTHERAPY ATG, mean (range)
Genzyme; mg/kg BW 8.7 (6.0–10.5) – –
Fresenius; mg/kg BW – 53 (45–60)
SEROTHERAPY PARAMETERS, median (range)
Start serotherapy, day
pre-HSCT
−6 (−8 to −3) −4 (−7 to −3) <0.001
Days ATG infusion 3 to 4 3 <0.001
Bodyweight, kg 35 (9 to 84) 25 (9 to 69) 0.141
Lymphocytes pre-ATG,
×109/L
0.2 (0.01 to 1.2) 0.05 (0.01 to 0.7) 0.10
CONDITIONING REGIMEN, n (%)
Chemotherapy + TBI 6 (14) 9 (56) 0.002
Chemotherapy 36 (86) 7 (44)
GvHD PROPHYLAXIS, n (%)
CSA + MTX 36 (86) 16 (100) 0.04
MTX + tacrolimus 1 (2)
CSA + MTX + MMF 5 (12)
PATIENTS AT RISK†, n (%)
CMV 29 (69) 14 (87) 0.19
EBV 41 (98) 13 (100)* 1.00
BW, body weight; CMV, cytomegalovirus; CsA, cyclosporine A; EBV, Epstein-Barr virus;
MTX, methotrexate; MMF, mycofenolate mofetil; NC, nucleated cells; TBI, total body
irradiation.
*Data of 1 patient (NC dose) and data of the EBV status of 3 donor-patients couples
pre-conditioning were lacking.
†
CMV and EBV seropositive patients and seronegative patients with a seropositive donor.
dilution of 1:4. To construct a reference curve, HUT-cells were
incubated with known concentrations of ATG (Thymoglobulin,
Genzyme). Active ATG is expressed in arbitrary units (AU).
Five mg ATG-GENZ was arbitrarily set to contain 5,000AU of
active ATG. The range of the standard curve (2-fold dilutions
in triplicate), is from 0.005 to 5 AU/mL. For validation of
the method, the ATG-GENZ reference curve was compared
with a reference curve constructed with similar rabbit IgG
concentrations of ATG-FRES (Supplementary Figure 1A). After
exposure to sample and standard dilutions the cells were
washed and incubated with Alexa Fluor 647 labeled goat anti-
rabbit IgG (Life Technologies, Carlsbad, CA, USA). Finally,
cells were washed and analyzed by flow cytometry on a FACS
Scan (Becton Dickinson Biosciences, Franklin Lakes, NJ, USA).
Mean fluorescence intensities obtained at the different standard
dilutions were plotted against the active ATG concentrations. The
lower limit of quantification for active ATGwas 0.1 AU/mL. Since
HUT-78 cells do not express all of the antigens expressed on
normal T-lymphocytes, we validated our data by comparing the
binding of active ATG in patients samples obtained at different
time points after ATG-GENZ or ATG-FRES infusion to HUT-78
cells with the binding to the T-cell fraction from peripheral blood
mononuclear cells (PBMC) (Supplementary Figure 1B).
In order to investigate the impact of active ATG exposure
on immune reconstitution, the day post-HSCT that the active
ATG level fell below 1 AU/mL was calculated. Above this level,
T-cells did not display numbers ≥ 100 cells/µL, in any of the
patients (15, 28).
All patients were screened for the presence of IgM, IgA,
and IgG anti-rabbit IgG (IgM, IgA, and IgG anti-ATG)
antibodies at 30 and 60 days post-HSCT using an ELISA
as described before (29). When anti-rabbit antibodies were
detected, earlier post-HSCT samples were analyzed as well.
In 6 patients (all ATG-GENZ), IgG antibodies against rabbit
IgG were detected. These patients were excluded from further
analysis of rabbit IgG levels from the time of detection of
these antibodies. Of these 6 ATG-GENZ patients with anti-
rabbit IgG antibodies, only one developed these antibodies
when active ATG was still present. Therefore, this patient
was excluded from the day of anti-rabbit IgG appearance
(day 18 post-HSCT) onwards for the active ATG analysis.
All 6 patients were included in the analysis of immune cell
recovery and clinical outcome analysis, since all of them
had an active ATG concentration <1.0 AU/mL at the time
anti-rabbit IgG became detectable. Because 1 AU/ml is the
critical threshold allowing T-cell recovery, the occurrence
of anti-ATG antibodies in these patients is considered not
biologically relevant.
Immune Cell Recovery
Engraftment was defined as the first day of 2 consecutive
measurements at which the absolute neutrophil count was
above 0.5 × 109/L in the absence of neutrophil infusions.
Absolute lymphocyte counts (leukocyte count and differential)
and lymphocyte subpopulations (CD3+ T-cells, CD3+CD4+,
and CD3+CD8+ T-cell subsets, CD3−CD56+/CD16+/− NK-
cells and CD19+/CD20+ B-cells) in PBMC were measured in
fresh material as part of routine clinical evaluation. In all patients
PBMC were investigated at 1, 2, 3, 6, and 12 months post-
HSCT by immunostaining and flow cytometry (Leiden: FACS
Calibur II, Becton Dickinson Biosciences, Franklin Lakes, NJ,
USA; Copenhagen: FC500 flow cytometer, Beckman Coulter,
Brea, CA, USA). Data were analyzed using BD CellQuest and
FACS Diva software.
Frontiers in Immunology | www.frontiersin.org 3 March 2019 | Volume 10 | Article 315
Oostenbrink et al. Importance of Lymphodepleting ATG Levels
Clinical Outcome Parameters
Incidences of acute and chronic GvHD were classified using
the Glucksberg and Shulman criteria, respectively (30, 31).
Acute GvHD referred to all grades (I-IV), whereas severe acute
GvHD was defined as grade III-IV. Chronic GvHD referred to
limited/extended. Data were censored for relapse and second
transplant. CMV and EBV infections/reactivations were defined
as two consecutive log serum viral DNA loads of at least 3.0
determined by real time quantitative (RQ) PCR in the first
100 days after transplantation (32, 33). Pretransplant CMV and
EBV serostatus of patient and donor were determined for all
HSCT couples and only CMV and EBV seropositive patients and
seronegative patients with a seropositive donor (at risk patients)
were included in CMV and EBV infection/reactivation analyses.
Overall survival (OS) was defined as time to death, regardless
of cause, or last follow-up (censoring), event-free survival (EFS)
referred to the time to disease reoccurrence, retransplantation,
death or last follow-up.
Statistical Analysis
All variables and outcome parameters were compared between
the ATG-GENZ and ATG-FRES groups. Differences in patient
characteristics among the treatment groups (Table 1) were
compared using Mann-Whitney rank tests for continuous
data, chi-square tests for categorical data and Fisher’s exact
tests for binomial data (SPSS 22). After dividing the ATG-
GENZ group in ATG-GENZ-high and ATG-GENZ-low, the
analyses to compare the ATG-GENZ subgroups and the
ATG-FRES group were performed by Kruskal-Wallis or chi-
square tests. Comparison of immune recovery at different
time points was done on log transformed data by T-tests
or ANOVA. The cumulative incidence of acute GvHD, viral
infections/reactivations and the recovery of immune cells were
calculated using the Kaplan-Meier method. The probabilities of
acute GvHD, chronic GvHD, relapse, viral reactivations and the
recovery of immune cells were compared with log-rank tests.
Graphs were made in Prism Graphpad 7.06 (Graphpad Software,
La Jolla, CA, USA).
RESULTS
Clearance of Rabbit IgG (Total ATG)
In this study we aimed to compare clearance of the two brands
of rabbit ATG, ATG-GENZ and ATG-FRES, given at different
dosages and analyze the consecutive immune reconstitution in a
homogeneous cohort of pediatric stem cell transplant recipients
transplanted in two HSCT Centers (Table 1). First we compared
the serum/plasma concentrations of rabbit IgG (total ATG) in
42 ATG-GENZ and 16 ATG-FRES treated patients during the
first 3 months after HSCT. The concentration of total ATG-FRES
at the day of HSCT was 5.8 times higher than that of ATG-
GENZ (median total ATG in ATG-FRES group 403µg/mL, range
306–485µg/mL; in ATG-GENZ group 65µg/mL, range 34–
193µg/mL; p< 0.0001, Figures 1A,B, 2A) and this corresponded
with the higher total dose of ATG-FRES given (Table 1). Three
weeks post-HSCT, around the expected time of engraftment,
the rabbit IgG concentration was decreased similarly for both
ATG brands, ATG-FRES from 403 to 148µg/mL (factor 2.7),
ATG-GENZ from 65 to 25µg/mL (factor 2.6, Figure 2A),
indicating that rabbit IgG from both brands was cleared at
equal rates.
Clearance of Active ATG
Subsequently, we determined the residual levels of T-cell binding
ATG, i.e., active ATG. The active ATG concentration at the
time of transplantation was 2.6 times higher for ATG-FRES than
for ATG-GENZ (median active ATG in ATG-FRES group 27.9
AU/mL range 12.8–74.0 AU/mL; ATG-GENZ group median 10.6
AU/mL range 2.5–30.3 AU/mL, p < 0.0001, Figures 1C,D, 2B).
However, 3 weeks post-HSCT, the active ATG concentration
in patients receiving ATG-FRES had decreased by a factor 164
(27.9 to 0.17 AU/mL), while in patients receiving ATG-GENZ
active ATG had decreased by a factor 16 (10.6 to 0.65 AU/mL
(Figure 2B). Thus despite the higher starting levels of active
ATG in ATG-FRES treated patients at transplantation, the rapid
clearance actually resulted in lower levels of active ATG at 3
weeks post-HSCT, i.e., in only 1 of 16 patients (6%) this level
was above 1 AU/mL whereas 17 out of 42 ATG-GENZ patients
(40%) still had levels above 1 AU/mL at this time point (p= 0.012,
Figures 1C,D).
Active ATG Levels in Relation to Dosage
Since in recent years the administered total doses of ATG
were lowered for both brands, we investigated whether the
dosage of ATG resulted in consistent differences in levels of
active ATG post-HSCT and in the dynamics of immune cell
reconstitution. We divided the ATG-GENZ group in patients
receiving a total dosage of 10 mg/kg (ATG-GENZ-high; n =
24) and patients receiving a reduced dosage ranging between
6 and 8 mg/kg (ATG-GENZ-low; n = 18). The ATG-FRES
group was divided in patients who received 60 mg/kg (ATG-
FRES-high; n = 9) and patients receiving 45 mg/kg (FRES-
low; n = 7) (Supplementary Table 1). The active ATG levels
in ATG-FRES-high and ATG-FRES-low patients at the time
of transplantation (median ATG-FRES-high 26.4 AU/mL vs.
ATG-FRES-low 28.0 AU/mL; p= 0.95) and at three weeks
post-HSCT (median ATG-FRES-high 0.13 AU/mL vs. ATG-
FRES-low 0.22 AU/mL; p = 0.47, Figure 3) did not differ
significantly. In contrast, patients receiving a high or low
dosage of ATG-GENZ did differ significantly at the time of
transplantation in the level of active ATG (ATG-GENZ-high
14.9 vs. ATG-GENZ-low 5.90 AU/mL; p < 0.0001) and at three
weeks (1.67 AU/mL vs. 0.11 AU/mL; p < 0.0001, Figure 3). No
relation between the number of lymphocytes pre-serotherapy
and active ATG level at the day of transplantation was seen in
this acute leukemia patient cohort (Supplementary Figure 2A).
At three weeks post-HSCT 15 out of 24 ATG-GENZ-high
patients (63%) had a level of active ATG above 1 AU/mL,
while only 2 out of 18 (11%) ATG-GENZ-low patients
still had an active ATG level above 1 AU/mL at this
time point (p = 0.001). The number of total nucleated
cells in the graft did not influence active ATG clearance
(Supplementary Figures 2B,C).
Frontiers in Immunology | www.frontiersin.org 4 March 2019 | Volume 10 | Article 315
Oostenbrink et al. Importance of Lymphodepleting ATG Levels
FIGURE 1 | Serum/plasma concentration of total Rabbit IgG (total ATG) and active ATG in ATG-GENZ (Genzyme, red) or ATG-FRES (Fresenius, green) treated
patients. Total Rabbit IgG (µg/mL) of ATG-FRES treated patients (B) was higher in comparison with ATG-GENZ treated patients (A), because of the higher dose of
ATG-FRES given, but clearance was comparable for both brands. Active ATG levels (AU/mL) of ATG-FRES treated patients (D), receiving 60 mg/kg (solid lines; n = 9)
or 45 mg/kg (dashed lines; n = 7), decreased fast and was only in 1 out of 16 patients (6%) above 1 AU/mL at 3 weeks post-HSCT. ATG-GENZ treated patients
(C) receiving 10 mg/kg (solid lines; n = 24) or 6–8 mg/kg (dashed lines; n = 18) showed more variance in clearance. At 3 weeks post-HSCT 15 out of 24 patients
(63%) receiving 10 mg/kg had active ATG levels above 1 AU/mL vs. only 2 out of 18 patients (11%) receiving 6–8 mg/kg. The horizontal dashed line at 1 AU/mL marks
the highest serum/plasma concentration at which T-cells can reappear in the blood. The vertical solid gray line is the expected time of neutrophil engraftment. Of note,
in the 6 patients receiving ATG-GENZ and showing a steep decline of rabbit ATG IgG antibodies against rabbit IgG were detected.
FIGURE 2 | Box plots of serum/plasma concentration of total Rabbit IgG (total ATG) and active ATG in ATG-GENZ (Genzyme, red) and ATG-FRES (Fresenius, green)
treated patients. (A) Total Rabbit IgG concentration in ATG-FRES treated patients at week 0 (day of graft infusion) and week +3 (expected time of neutrophil
engraftment) is significantly higher in comparison with ATG-GENZ treated patients. (B) Active ATG concentration at week 0 in ATG-FRES treated patients is
significantly higher in comparison with ATG-GENZ treated patients, but at week +3 the serum/plasma level of active ATG in ATG-FRES treated patients is lower than
in ATG-GENZ treated patients (0.17 vs. 0.65 AU/mL).
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FIGURE 3 | Box plots of serum/plasma concentration of active ATG in
ATG-GENZ (Genzyme) and ATG-FRES (Fresenius) treated patients depending
on the given total ATG dose. At week 0 (day of graft infusion) the ATG-GENZ
patients receiving a total ATG dose of 10 mg/kg had a significantly higher
serum/plasma level of active ATG than the 6–8 mg/kg receiving patients.
Active ATG in ATG-FRES treated patients was at week 0 comparable between
45 and 60 mg/kg total ATG dose receiving patients and higher than in
ATG-GENZ treated patients. At week +3 post-HSCT the serum/plasma level
of active ATG in ATG-GENZ treated patients was still strongly dependent on
the given dose (1.29 and 0.11 AU/mL), but the active ATG concentration in
ATG-FRES treated patients was comparably low regardless of ATG dosing
(0.12 and 0.21 AU/mL, respectively). The horizontal dashed line at 1 AU/mL is
the highest serum/plasma concentration at which T-cells can recover.
Immune Recovery in ATG-GENZ
Subgroups and ATG-FRES Group
Patients in the ATG-FRES-high and ATG-FRES-low subgroups
did not differ in active ATG levels at 3 weeks after HSCT
(Figure 3) and their immune recovery was comparable: CD3+
T-cell recovery at 4 weeks, ATG-FRES-high 169 cells/µL, ATG-
FRES-low 221 cells/µL, p = 0.6 (Supplementary Table 2).
Therefore, data on immune recovery will be compared
between the two ATG-GENZ subgroups and one combined
ATG-FRES group.
There was no difference in engraftment between the three
groups, i.e., ATG-GENZ-high 22 days; ATG-GENZ-low 21 days
and ATG-FRES 23 days; p = 0.86 (Table 2). However, T-cell
(CD3+) numbers at 1 month post-HSCT were significantly
lower in ATG-GENZ-high patients than in ATG-GENZ-low
and ATG-FRES patients (Figure 4). T-cell numbers in these
last two groups did not differ and were comparable to the
numbers in the patients who did not receive serotherapy (ATG-
GENZ-high: 15 cells/µL, ATG-GENZ-low: 165 cells/µL, ATG-
FRES: 190 cells/µL; Anova p < 0.0001). A similar observation
was made for the CD4+ and CD8+ T-cell subsets. The
number of CD56+CD16± NK-cells at 1 month post-HSCT was
significantly higher in ATG-GENZ-high patients (ATG-GENZ-
high: 454 cells/µL, ATG-GENZ-low: 231 cells/µL, ATG-FRES:
182 cells/µL; Anova p= 0.008). The number of B-cells was very
low for both brands at 1month post-HSCT, but at 2 and 3months
TABLE 2 | Clinical outcome parameters in the ATG-Genzyme-high,
ATG-Genzyme-low, and ATG-Fresenius group.
ATG
Genzyme
10 mg/kg
ATG
Genzyme
6–8 mg/kg
ATG
Fresenius
p-value
Number of patients 24 18 16
Engraftment failure, n (%) 0* 0 0
Engraftment, day after
HSCT median (range)
22 (13–46) 21 (12–30) 23 (14–27) 0.86
Acute GvHD, n (%) 0.024†
All grades 4 (17) 8 (44) 9 (56)
Grade I 2 (8) 2 (11) 3 (19)
Grade II 1 (4) 2 (11) 6 (38)
Grade III–IV 1 (4) 4 (22) 0 0.025†
Chronic GvHD, n (%) 0.97
Limited 2 (8) 1 (6) 0
Extended 4 (17) 2 (11) 2 (13)
Viral infections, n (%) of patients at risk
CMV 5 of 14 (36) 7 of 15 (47) 4 of 14 (29)* 0.62†
EBV 7 of 23 (30) 4 of 18 (22) 2 of 13 (15)** 0.28†
Relapse 4 (16) 4 (22) 3 (18) 0.54†
Transplant related
mortality <100 days
1 0 0
Overall survival, months
median (range)
62 (1–92) 33 (4–53) 38 (4–84) 0.15†
CMV, cytomegalovirus; EBV, Epstein-Barr virus; GvHD, Graft-vs.-Host Disease.
*One patient died (day +18) before engraftment.
**EBV status of three donor-patients couples pre-conditioning were lacking.
†
Long rank test.
post-HSCT ATG-GENZ-high patients had a significantly higher
number of B-cells in comparison with ATG-GENZ-low (at 2
months p = 0.03; at 3 months; p = 0.01, Figure 4). No effect
of TBI on immune recovery was observed in this study cohort
(Supplementary Figure 3).
Clinical Outcome
The impact of differences in active ATG clearance and immune
reconstitution on clinical outcome was investigated (Table 2).
The overall incidence of acute GvHD (grade II-IV) tended to be
lower in the ATG-GENZ-high subgroup (p = 0.118, Figure 5).
GvHD grade III-IV did not occur in the ATG-FRES group, only
in 1 out of 24 ATG-GENZ-high patients, and was significantly
more frequent in ATG-GENZ-low patients (p = 0.025). The
incidence of chronic GvHD, limited or extended, was comparable
between the three groups (Table 2), and there was no difference
in the incidence of relapse, CMV or EBV infection/reactivation
and overall survival (OS, Supplementary Figure 4) between the
three groups.
DISCUSSION
Studies on active ATG in HSCT patients have mainly been
performed with ATG-Genzyme (7–9, 14, 15, 25, 34–36). Our
current study is one of the few on ATG-Fresenius (16, 37) and
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FIGURE 4 | Immune cell recovery post-HSCT in ATG-FRES (Fresenius) treated patients in comparison with high (ATG-GENZ-high) and low dose (ATG-GENZ-low)
ATG-GENZ (Genzyme) treated patients. CD3 T-cell and CD4 and CD8 T-cell subset numbers differed significantly at one month post-HSCT between the two ATG
treated groups. ATG-GENZ-high patients recovered significantly slower for CD3, CD4, and CD8 compared to the ATG-FRES and ATG-GENZ-low treated patients. In
contrast to the T-cell recovery, NK-cells recovered fast after HSCT reaching normal levels within 1 month. The highest level of NK-cell numbers were observed at one
month in the ATG-GENZ-high group. B-cell recovery in all ATG groups returned to normal levels at 6 months post-HSCT with a significantly higher number of B-cells
at 2 and 3 months in the ATG-GENZ-high compared to the ATG-GENZ-low and ATG-FRES treated patients, respectively. Dotted horizontal lines represent the 5th and
95th percentiles of cell numbers in 28 healthy age-matched donors. Gray line: patients transplanted for acute leukemia with a graft from an HLA-identical sibling donor
without receiving ATG in the conditioning.
FIGURE 5 | The effect of ATG brand and dosing on acute GvHD. Although not significant, acute GvHD (grade II-IV) occurred less frequently in ATG Genzyme high
dose (ATG-GENZ-high) receiving patients compared to patients receiving a low dose of ATG-Genzyme (ATG-GENZ-low) or ATG Fresenius (ATG-FRES). For severe
acute GvHD (grade III-IV), there was a significant difference between the three ATG groups. Severe acute GvHD occurred most frequently in the ATG-GENZ-low group.
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the first one comparing the active components of the two rabbit
ATG products.
While rabbit IgG (total ATG) of both products was cleared
at similar rates (38), active ATG-FRES was cleared from the
circulation faster than active ATG-GENZ, despite higher dosing
of ATG-FRES and the presence of higher levels of active ATG
at the day of transplantation. ATG-FRES was administered in
two different dosages (the historical dosage of 60 mg/kg vs. the
more recently given dosage of 45 mg/kg), but resulted in similar
active ATG levels at 3 weeks after HSCT. The levels of active ATG
in ATG-FRES treated patients were below the critical level for
T-cell reconstitution of 1 AU/mL (15, 28) in all but one patient
before 21 days post-HSCT. Thus, for ATG-FRES reducing the
total dosage from 60 to 45 mg/kg has little impact on its in vivo
persistence, probably because of the short half-life of its active
component (16).
In contrast, there was a large variation in the day after HSCT
when active ATG-GENZ fell below the level of 1 AU/mL, ranging
from 0.5 to 7 weeks (14). Treatment with a lower ATG-GENZ
dosage resulted in lower levels of active ATG at the day of HSCT
as well as 3 weeks thereafter (9). For ATG-GENZ reducing the
total dosage from 10 mg/kg to 6–8 mg/kg resulted in an increase
from 11 to 63% of patients who had a level below 1 AU/mL
at three weeks. This clearly had an impact on circulating T-cell
numbers at 1 month after HSCT.
It is intriguing that active ATG from the two products
is cleared at different rates. It can be assumed that this
is due to differences in manufacturing, since ATG-FRES is
absorbed to human placental cells and erythrocytes, while
ATG-GENZ is absorbed to erythrocytes only (39). Another
explanation might be the differences in antigens recognized
by the polyclonal antibodies in both products. ATG-FRES is
raised against the lymphoblastic Jurkat cell line. In contrast,
ATG-GENZ is generated using human thymocytes expressing
a different array of antigens as potential immunogens. As a
result, the relative concentrations of antibodies recognizing
various antigens expressed on T-cells vary between ATG-
GENZ and ATG-FRES. For example, ATG-GENZ contains
more antibodies recognizing CD8, CD11a, CD18, CD44, CD52,
CD99 while ATG-FRES recognizes more CD5, CD98, and
CD147 (5, 40), although other studies reported different
antigens (41, 42).
ATG dose finding is pivotal in the delicate balance between
T-cell elimination and post-HSCT immune reconstitution and
has been the subject of a number of studies, although levels
of active ATG were not always measured. For ATG-GENZ, a
large variation in dosing has been reported, varying between
2.5 and 60 mg/kg (7, 10, 14, 43–50). In studies in which two
dosages of ATG-GENZ were directly compared, the incidence
of acute and/or chronic GvHD was lower in the group of
patients who received a higher dose, as we observed in the
present study (45, 47, 48, 51, 52). In contrast, when different
dosages of ATG-FRES were compared in their efficiency of
preventing GvHD, the differences between high and low doses
were not obvious (27, 53, 54). The lack of an effect of the
ATG-FRES dosage can be explained by our observation that
active ATG-FRES is cleared rapidly and uniformly from the
circulation. Likewise, reported data on T-cell reconstitution
were less correlated with dose variation in ATG-FRES (45–
60 mg/kg) in contrast to ATG-GENZ (6–10 mg/kg) (46, 48,
54). In retrospect, the reported effects of dosing of ATG-
GENZ and lack of dosage effects in case of ATG-FRES may
be explained by the differences in clearance of active ATG of
both products.
Only a few studies have reported a comparison between the
two brands of rabbit ATG with respect to T-cell reconstitution
and clinical outcome after HSCT, however without taking
clearance of the T-cell binding component (active ATG) into
account (10, 17, 19) Although the number of patients in our
study is limited, especially in the ATG-FRES group, none of
the patients in the ATG-FRES group developed acute GvHD
higher than grade II, whereas 22% of the patients in the ATG-
GENZ-low group developed GvHD grade III or IV. Since
time when active ATG levels fell below 1 AU/mL and T-cell
reconstitution were comparable between these two groups, it
would be interesting to investigate the recovery of functional
T-cell subsets. Other studies have reported no difference in the
occurrence of acute GvHD between patients receiving ATG-
GENZ (range 5–10 mg/kg) and patients receiving ATG-FRES
(range 20–60 mg/kg) (10, 17, 55). Protection from GvHD grade
III-IV by ATG was reported before, but this was not limited to
ATG-FRES (56).
From this retrospective study, we conclude that the two rabbit
ATG products have different biopharmaceutical properties.
During the last few years, physicians have empirically lowered
the dosages of ATG in order to enhance T-cell reconstitution
to prevent viral complications while maintaining sufficient
immunosuppressive potential to prevent GvHD. Differences in
dosing of ATG-FRES have little effect on the time when active
ATG levels fall below 1 AU/mL and, therefore, are not expected
to change functional T-cell reconstitution. However, reducing
the dosing of ATG-GENZ results in less variable serum/plasma
levels and, together with less variable clearance rates, this leads
to a more predictable time frame at which the serum/plasma
levels of active ATG decrease below the critical level of 1
AU/mL. Dosing of ATG-GENZ in the HSCT setting, therefore,
appears more critical than dosing of ATG-FRES. However, in
practice dosages of both products have to be further optimized,
depending on the HSCT platform. Because of the observed
differences in PK/PD of active ATG after administration of
the two ATG brands, choices to use one or the other and
the applied dosage should be carefully considered in clinical
decision making.
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Supplementary Figure 1 | Active ATG Genzyme and Fresenius measurements
on HUT-78 cells and T-cells in PBMC. (A) To validate the active ATG measurement
the ATG-GENZ and ATG-FRES reference curves on HUT-78 cells were compared.
The ATG-FRES curve is parallel shifted in comparison with the ATG-GENZ curve
(factor difference = 2.6). These results confirmed the previously published
observation that ATG-FRES contains less active ATG per µg rabbit IgG than
ATG-GENZ(5). (B) The binding of active ATG (ATG-FRES or ATG-GENZ) in
patients samples obtained at different time points after ATG infusion to HUT-78
cells was compared with the binding to the T-cell fraction in PBMC. For a wide
range of concentrations of active ATG the results showed a good correlation for
both products using either HUT-78 or T-cells in PBMC as target.
Supplementary Figure 2 | The effect of lymphocytes pre start serotherapy and
the total nucleated cell dose in the graft on the active ATG level. (A) No relation
between the number of lymphocytes pre start serotherapy and active ATG level at
the day of transplantation was observed in this acute leukemia patient cohort.
(B) Patients were ordered based on the brand of ATG, the dose of ATG and the
amount of nucleated cells in the graft, creating 6 different groups. The
ATG-Genzyme high (10 mg/kg) and low (6–8 mg/kg) dosage treated patients
getting a high number of nucleated cells, received a comparable number of
nucleated cells as the Fresenius (both high 60 mg/kg and low 45 mg/kg) treated
patients. (C) Factor of decrease of the active-ATG level at week 1 vs. 0 (day of
transplantation) was highest in the Fresenius groups and was significantly different
between the 4 ATG groups containing patients that received high numbers of
nucleated cells (Kruskal-Wallis test: p = 0.0018). No significant difference in the
decrease of this factor (ns, Genzyme 10 mg/kg group low vs. high NC: p = 0.536,
Genzyme 6–8 mg/kg group low vs. high NC: p = 0.231) was observed in the
ATG-Genzyme treated groups between patients that received a low or a high
number of nucleated cells.
Supplementary Figure 3 | The effect of TBI on T-cell recovery. No significant
difference in T-cell recovery at 1, 2, and 3 months post-HSCT was observed
between patients treated with or without TBI in the conditioning regimen. The
Genzyme-low group was left out of this analysis since only one patient in this
group received TBI. Figure shows geomeans and 95% confidence interval.
Supplementary Figure 4 | The effect of ATG brand and dosing on clinical
outcome parameters. No significant difference was observed between the
ATG-Fresenius and the two ATG-Genzyme groups for CMV and EBV
infection/reactivation (up to 6 months after HSCT), relapse of the acute leukemia
or for overall survival (up to 5 years post-HSCT). For CMV and EBV only patients
at risk (numbers in the table below the graph) were included in the analyses.
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